Results 231 to 240 of about 2,945,737 (301)

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

Molecular Oncology, EarlyView.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos, Gilar Gorji‐bahri, Lejla Gradjan, Julia Zajac, Kacper Gil, Yvonne Thokozile Nduku, Anna M. Blom   +6 more
wiley   +1 more source

A comprehensive systematic review and meta-analysis of the safety of procedural sedation in pediatric emergency rooms. [PDF]

Ital J Pediatr
Alsabri M, Rath S, Elbataa A, Shehab MA, Chhetri J, Amer MS, Abdelwahab OA, Sleem R, Siddiq A, Kurian E.   +9 more
europepmc   +1 more source

Pre‐analytical optimization of cell‐free DNA and extracellular vesicle‐derived DNA for mutation detection in liquid biopsies

Molecular Oncology, EarlyView.
Pre‐analytical handling critically determines liquid biopsy performance. This study defines practical best‐practice conditions for cell‐free DNA (cfDNA) and extracellular vesicle–derived DNA (evDNA), showing how processing time, storage conditions, tube type, and plasma input volume affect DNA integrity and mutation detection.
Jonas Dohmen, Lucrezia De Santis, Bret M. Stephens, Vincent Bernard, Jörg C. Kalff, Lara Braun, Phillipp Leyendecker, Johannes Röttgen, Daniel Weissinger, Anirban Maitra, Paola A. Guerrero, Alexander Semaan   +11 more
wiley   +1 more source

Interrogating the immune landscape of microsatellite stable RAS‐mutated colon cancer

Molecular Oncology, EarlyView.
COLOSSUS project RAS‐mutated MSS colon cancer study explored transcriptomics and immune cell density by immunohistochemistry (IHC), Immunoscore (IS), ISIC/TuLIS scores, mutation counts, and detected different prevalences but similar microenvironment composition across immune markers with clinical relevance for future immunotherapy combination ...
Rodrigo Dienstmann, Eduardo García‐Galea, Alice O'Farrell, Zak Kinsella, Maxime Meylan, Florent Petitprez, Ingrid Arijs, Tom Venken, Hari Ps, Adrian Lärkeryd, Ian Miller, Janick Selves, Nadja Meindl‐Beinker, Fiorella Ruiz‐Pace, Elena Élez, Raquel Comas‐Navarro, Frank Lincoln, Dirk Fey, Gift Nyamundanda, Aoife Nolan, Joern Lewin, Raquel Perez‐Lopez, Jonathan Briody, Kathleen Bennett, Walter Kolch, David Matallanas, Alexander Kel, Enrique Arenas, Joaquín Arribas, Bart Ghesquière, Josep Tabernero, Julie Meilleroux, Deborah McNamara, Ray McDermott, Marvin Lim, Mary O'Reilly, Brian Bird, Lisa Stack, Lucia Moloney, Patrick Morris, Keith Egan, Maciej Milewski, Lars Scheuer, Joachim Behringer, Georg Bolz, Ramon Salazar, Cristina Santos, Andrea Ruiz, Orla Casey, Verena Murphy, Matthias Ebert, Livio Trusolino, Diether Lambrechts, Anguraj Sadanandam, Catherine Sautès‐Fridman, Jochen Prehn, Paolo Nuciforo, Jacques Fieschi, Florence Monville, Darran O'Connor, Wolf Fridman, Annette Byrne   +61 more
wiley   +1 more source

Discrete Time Neural Network Models to Address Time-Varying Predictor Importance: An Illustration in Predicting Mortality Over Different Time Horizons. [PDF]

IEEE J Biomed Health Inform
Wang M, Engelhard MM, Pun PH, Goldstein BA.   +3 more
europepmc   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Modulating the gut microbiome to enhance cancer immunotherapy: a systematic review and Meta-Analysis of probiotics and FMT as adjuncts. [PDF]

BMC Cancer
Hu S, Luo C, Wan S, Zhang S, Li N, Liu G, Zhao LY.   +6 more
europepmc   +1 more source

Assessment of genetically modified cotton GHB614 × T304-40 × GHB119 × COT102 (application EFSA-GMO-ES-2017-147). [PDF]

EFSA J
EFSA Panel on Genetically Modified Organisms (GMO), Casacuberta J, Barro F, Braeuning A, de Maagd R, Epstein MM, Frenzel T, Gallois JL, Koning F, Messéan A, Moreno FJ, Nogué F, Savoini G, Schulman AH, Tebbe C, Veromann E, Ardizzone M, De Sanctis G, Dumont AF, Gennaro A, Gómez Ruiz JÁ, Goumperis T, Kagkli DM, Lenzi P, Camargo AM, Neri FM, Piffanelli P, Raffaello T.   +27 more
europepmc   +1 more source

A practical guide to unbinned unfolding. [PDF]

Eur Phys J C Part Fields
Canelli F, Cormier K, Cudd A, Gillberg D, Huang RG, Jin W, Lee S, Mikuni V, Miller L, Nachman B, Pan J, Pani T, Pettee M, Song Y, Acosta FT.   +14 more
europepmc   +1 more source

Beyond the Hazard Ratio: Rethinking Survival Reporting in Cardio-Oncology With Restricted Mean Survival Time. [PDF]

JACC CardioOncol
Maselli-Schoueri JH, Saibil SD, Gabriel da Silva Negrini V, Neto AS, Butler M.   +4 more
europepmc   +1 more source